ipilimumab at antigen release — addresses threshold drift
ipilimumab (ctla4 brake release) is predicted to act at the antigen release step of the cancer-immunity cycle, addressing threshold drift — threshold moves out of reach of normal loading current. Capacitor sometimes fires, sometimes doesn't; unpredictable activation.
What this is
The Living Scorecard is the lab's open record of structural predictions. Each hypothesis names a candidate intervention, where in the cycle it is predicted to act, the failure mode it is predicted to address, and the evidence available when the prediction was made.
Predictions are locked with timestamps before they can be tested. We generate them daily — many more than any one person can chase — so the field can see what the framework claims structurally, ahead of the data. Some will hold. Some will be refuted. Both stay on the page. Falsifiability is the point, not being right.
Structural argument
At the antigen release step of the cancer-immunity cycle (the capacitor regime at position P1), ipilimumab is predicted to act on the substrate via ctla4 brake release. This addresses threshold drift, the failure mode where threshold moves out of reach of normal loading current. Capacitor sometimes fires, sometimes doesn't; unpredictable activation. Structural basis: the intervention's regime-type class matches the position's regime, and the failure is one of the recognised failure modes for that regime.
rule_r13(required) — Combinatorial candidate is grounded in R13's position-to-state table, which determines which interventions are structurally addressable at which positions.
Substrate
- Domain
- domain_cellular_biology
- Cycle
- cycle_l4_canonical
- Position(s)
- position_p1
- Failure modes
- failure_threshold_drift
Evidence at generation
"ipilimumab" AND "cancer immunotherapy"
- PMID 38828984
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
- PMID 35810989
Colorectal cancer immunotherapy-Recent progress and future directions.
- PMID 35403841
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
- PMID 29778737
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
- PMID 22193102
Cancer immunotherapy comes of age.
Targets: CHEMBL2364164
inhibitor
ipilimumab cancer immunotherapy
- NCT04090775
Metastatic Prostatic Adenocarcinoma
Primary: Primary endpoint: PSA decline
- NCT04943848
Diffuse Intrinsic Pontine Glioma
Primary: Safety and Tolerability: Dose limiting toxicities of rHSC-DIPGVax
- NCT03416244
Esophageal Cancer
Primary: Overall survival
- NCT06492421
Lung Cancer
Primary: pCR rate for the study groups
- NCT05219435
Urothelial Cancer
Primary: progression-free survival (PFS)
Status timeline
- Draft2026-05-28T22:31:31Z
Generated by combinatorial walker (v0.1.0).
by system
- Published2026-05-28T22:31:31Z
First hypothesis approved for the public Living Scorecard. Top composite-ranked candidate from the daily run.
by raimo